Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

BofA raised the firm’s price target on Amgen (AMGN) to $275 from $256 and keeps an Underperform rating on the shares. Q4 results were slightly ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

Most of the Dow Jones is testing into the high side as broad-market sentiment generally improves. Familiar market favorites Amgen (AMGN) and Nvidia (NVDA) are climbing on Wednesday, gaining 5.5% and 4 ...

The blue-chip index, up 0.6%, was heading for its second consecutive gain this week. The Dow was riding higher on gains in ...